MedDataX Logo

Efficacy and Safety of Middle Meningeal Artery Embolization for Treatment of Intractable Migraine

NCT ID: NCT06029153

Last Updated: 2024-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-15

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a single-arm, self-controlled clinical trial that explores and evaluates the efficacy of middle meningeal artery embolization with coil in improving migraine symptoms. The main objectives of the study are to evaluate the effectiveness and safety of the treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a single-arm, self-controlled, open-label, single-center clinical trial that explores and evaluates the efficacy of middle meningeal artery embolization with coil in improving migraine symptoms. The inclusion criteria consist of patients with or without aura migraines, who have experienced persistent, chronic migraines for at least 3 months before screening, and have shown resistance to at least two or more drug treatments, with unsatisfactory therapeutic effects, intolerable side effects, or contraindications. The main objectives of the study are to evaluate the effectiveness and safety of the treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Migraine Middle meningeal artery Embolization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Self-control
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Middle meningeal artery embolization

Middle meningeal artery embolization with coil.

Group Type EXPERIMENTAL

Middle meningeal artery embolization

Intervention Type PROCEDURE

Middle meningeal artery embolization with coil.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Middle meningeal artery embolization

Middle meningeal artery embolization with coil.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Voluntary written informed consent.
2. Age 18\~80 years old (inclusive), regardless of gender.
3. Migraine was diagnosed by clinicians, according to The International Classification of Headache Disorders,3rd Edition
4. Patients with intractable migraine or refractory headache with migraine duration of more than 3 months and recurring migraine in the past 90 days before screening.
5. Patients who take two or more drugs are not satisfied with the therapeutic effect, the side effects of drug treatment are difficult to tolerate or have contraindications.
6. Headache frequency should be confirmed within 30 days before screening.
7. Patients with good compliance, willing and able to follow the requirements of treatment and follow-up observation.

Exclusion Criteria

1. Patients with cervical spondylosis and secondary headaches such as otogenic, nasal, and odontogenic patients with a history of trigeminal autonomic headache, other definite causes of headache, or secondary headache.
2. Patients without suitable vascular access.
3. Patients scheduled for surgery within 90 days.
4. The life expectancy of patients is less than 12 months.
5. History of contrast agent allergy.
6. Lactating or pregnant women, or patients with a fertility plan within 1 year.
7. The clinical status of the patient was extremely poor, with an mRS Score ≥4.
8. Participants who had participated in clinical studies of other drugs or medical devices before enrollment and did not meet the primary study endpoint time limit.
9. The investigator judged that the patient had poor compliance and could not complete the study as required.
10. The patient had a clear history of allergies to embolic materials such as Nitinol alloy, cobalt-based alloy, and platinum-tungsten alloy.
11. Patient was allergic to the contrast agent.
12. Patients with other diseases limit their participation in the study, cannot follow up, or affect the scientific integrity of the study.
13. Patients have clotting disorders or are on anticoagulant therapy.
14. Patients have a history of opioid addiction.
15. Researchers believe that patients who are not suitable to participate in this trial.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Affiliated Hospital Of Guizhou Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zeguang Ren

Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zeguang Ren, MD. PhD.

Role: STUDY_CHAIR

The Affiliated Hospital Of Guizhou Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Affiliated Hospital of Guizhou Medical University

Guiyang, Guizhou, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FAST-EM

Identifier Type: -

Identifier Source: org_study_id